

IN THE SPECIFICATION:

Page 4, please rewrite in entirety as follows:

## SUMMARY OF THE INVENTION

This invention provides an isolated strain of Hepatitis B virus designated Human Hepatitis B Virus Surface Antigen-'S' -  
5 145 Singapore Strain (Glycine to Arginine) which constituent viral genome is deposited under Accession Nos. P97121504, P97121505 and P97121506 with the European Collection of Cell Culture on 15<sup>th</sup> December 1997.

10 This invention also provides an isolated nucleic acid encoding a polypeptide which is a mutant major surface antigen of a strain of hepatitis B virus, such polypeptide having an amino acid sequence which differs from the amino acid sequence of a major surface antigen of a wild type  
15 hepatitis B virus in that the amino acid at position number 145 of such polypeptide is an arginine rather than a glycine.

This invention provides a method of producing the polypeptide in purified form and the resulting purified  
20 polypeptide which is a mutant major surface antigen of a strain of hepatitis B virus, such polypeptide having an amino acid sequence which differs from the amino acid sequence of a major surface antigen of a wild type hepatitis B virus in that the amino acid at position number 145 of such  
25 polypeptide is an arginine rather than a glycine.

This invention provides an oligonucleotide of at least 15 nucleotides capable of specifically hybridizing with sequences of only the mutant viral strain of hepatitis B  
30 virus.

This invention provides a method of obtaining antibodies to a polypeptide which is a mutant major surface antigen of a strain of hepatitis B virus and the antibodies produced.

35 This invention provides uses of the above-described polypeptide, antibodies or nucleic acid for determining whether a subject is infected with the above-described viral

Page 6, second paragraph, please rewrite as follows:

A map showing positions of oligonucleotide V1 to V13 for use in the Strategy of cloning and sequence determination of the same hepatitis B viral genome that is shown in Fig 1.

Page 11, please rewrite in entirety as follows:

Further, this invention provides a vector comprising an isolated nucleic acid encoding a peptide, wherein the peptide is encoded by a nucleic acid molecule comprising nucleotides 527 through 595 of SEQ. I.D. No. 1.

5

In both of the above-identified vectors, the vector may comprise viral DNA.

10 This invention also provides a host vector system for the production of a polypeptide which comprises the above-described vectors in a suitable host.

15 This invention also provides a method of producing a polypeptide or a peptide which comprises growing the host vector systems described above, under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.

20 This invention further provides a method of obtaining a polypeptide or a peptide in purified form which comprises: (a) introducing the above-described vectors into a suitable host cell; (b) culturing the resulting host cell so as to produce the polypeptide; (c) recovering the polypeptide produced in step (b); and (d) purifying the polypeptide so  
25 recovered.

30 This invention further provides a purified polypeptide which is a mutant major surface antigen of a strain of hepatitis B virus, such polypeptide having an amino acid sequence which differs from the amino acid sequence of a major surface antigen of a wild type hepatitis B virus in that the amino acid at position number 145 of such polypeptide is an arginine rather than a glycine. One means of obtaining the polypeptide is by the above-described method.

35

This invention also provides a purified peptide, wherein the peptide has an amino acid sequence comprising amino acid residues 298 through 320 of the amino acid sequence

Page 15, please rewrite in entirety as follows:

having an amino acid sequence which differs from the amino acid sequence of a major surface antigen of a wild type hepatitis B virus in that the amino acid at position number 145 of such polypeptide is an arginine, rather than a glycine, and wherein the determining of step (b) comprises:

5 (i) translating the mRNA under suitable conditions to obtain an amino acid sequence; and (ii) comparing the amino acid sequence of step (i) with the amino acid sequence of an isolated nucleic acid which encodes a polypeptide, wherein

10 the polypeptide has an amino acid sequence substantially identical to amino acid residues 174 through 400 of the amino acid sequence designated SEQ. I.D. No. 3 so as to thereby determine whether the nucleic acid sample is, or is derived from, a nucleic acid which encodes the polypeptide. A

15 further example is where the determining of step (b) comprises: (i) amplifying the nucleic acid present in the sample of step (a); and (ii) detecting the presence of polypeptide in the resulting amplified nucleic acid.

20 This invention provides the use of an antibody that recognizes a polypeptide which is a mutant major surface antigen of a strain of hepatitis B virus for determining whether the subject has a predisposition for hepatocellular carcinoma, wherein such determination comprises: (a)

25 obtaining an appropriate nucleic acid sample from the subject; and (b) determining whether the nucleic acid sample from step (a) is, or is derived from, a nucleic acid encoding a polypeptide which is a mutant major surface antigen of a strain of hepatitis B virus, such polypeptide having an amino

30 acid sequence which differs from the amino acid sequence of a major surface antigen of a wild type hepatitis B virus in that the amino acid at position number 145 of such polypeptide is an arginine, rather than a glycine, by contacting the sample under appropriate conditions to bind to

35 the antibodies of claim 35 so as to determine whether the subject has a predisposition for hepatocellular carcinoma.

This invention also provides use of antibodies capable of

Page 18, please rewrite in entirety as follows:

The actual effective amount will be based upon the size of the polypeptide, the biodegradability of the polypeptide, the bioactivity of the polypeptide and the bioavailability of the polypeptide. If the polypeptide does not degrade quickly, is bioavailable and highly active, a smaller amount will be required to be effective. The effective amount will be known to one of skill in the art; it will also be dependent upon the form of the polypeptide, the size of the polypeptide and the bioactivity of the polypeptide. Use of an adjuvant for example, would lower the required amount of the polypeptide. One of skill in the art could routinely perform empirical activity tests to determine the bioactivity in bioassays and thus determine the effective amount.

Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

This invention further provides a composition comprising a peptide, wherein the peptide has an amino acid sequence comprising amino acid residues 298 through 320 of the amino acid sequence designated SEQ. I.D. No. 3 or derivative thereof, the amounts of such peptide being effective to



Page 32, please rewrite in entirety as follows:

an early stage of infection.

In addition, these features allow accurate diagnosis of patients at an early stage of the disease and also help to  
5 remove with higher efficiency blood contaminated with vaccine-induced mutant hepatitis B virus through using a screening test of donor bloods.

Proteins and their antibodies under the present invention can  
10 be utilized for development of prophylactic and therapeutic vaccines, as well as, immunological pharmaceuticals. Sequence information on structural genes of these mutant viruses will be helpful in developing detection systems of the relevant protein antigens and antibodies.

15 Antigen-antibody complexes can be detected by known methods. Specific monoclonal and polyclonal antibodies can be raised by immunizing animals such as mice and rabbits with peptides or proteins specific to mutant vaccine-induced hepatitis B  
20 viruses. Inhibitory antiviral agents can be designed and targeted against these proteins and molecules in cell culture or in vivo.

The present invention is based on studies on an isolated virus  
25 genome with a vaccine-induced mutation at amino acid residue 145 (Glycine to Arginine) of the major surface antigen. The invention makes possible highly specific detection of these vaccine-induced mutant hepatitis B virus and provides material such as protein, polyclonal and monoclonal antibodies for  
30 development of such detection system.

We have evidence showing that when expressed in a mammalian expression system, the major surface antigen (HBsAg) of the mutant HBV reported in our invention is detected as a 22kDa  
35 protein on a Coomassie-blue stained SDS-PAGE gel, whereas the wild type HBsAg is detected as a 25kDa protein. Since the only glycosylation site on the HBsAg is located in close proximity (Asparagine at position 146) to the mutation at

Please delete the sequence listing and substitute the sequence listing attached hereto.